RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises in building a company primarily focused on U.S commercialization and development of drugs for gastrointestinal diseases, infectious diseases and oncology.
Our FDA-approved drug, Talicia®, is promoted in the U.S. by a dedicated and experienced sales team, focused on driving increasing revenues.
We have also built an exciting, advanced and largely de-risked R&D pipeline of proprietary late-stage clinical development drug candidates addressing major unmet medical needs.